Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 5/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | ATR | Q13535 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.39 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13604152 | 0.80 | RIPK1 (0.53) | RIPK1BTKTBK1ALK | |
| SCHEMBL31064959 | 0.74 | RIPK1 (1.00) | RIPK1POLBHRH4 | |
| SCHEMBL4068059 | 0.74 | RIPK1 (0.55) | RIPK1BTKTBK1ALK | |
| SCHEMBL4063817 | 0.71 | RIPK1 (0.59) | RIPK1POLBBTKTBK1ALK | |
| SCHEMBL4467935 | 0.71 | RIPK1 (0.64) | RIPK1BTKTBK1ALK | |
| SCHEMBL4068055 | 0.70 | RIPK1 (0.55) | RIPK1BTKTBK1ALKHDAC4 | |
| SCHEMBL4472467 | 0.70 | RIPK1 (0.52) | RIPK1BTKTBK1ALKHDAC4 | |
| SCHEMBL24596889 | 0.70 | RIPK1 (0.68) | RIPK1POLBBTKTBK1ALK | |
| SCHEMBL13604150 | 0.69 | RIPK1 (0.61) | RIPK1POLBBTKTBK1ALK | |
| SCHEMBL4065929 | 0.68 | RIPK1 (0.60) | RIPK1POLBBTKTBK1ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7625894-B2 | Pyrrolo[2,3-d]Pyrimidines as Protein Tyrosine Kinase Inhibitors | NOVARTIS AG (CH) | 2009-12-01 | — | — | US | disclosed |
| EP-1718651-B1 | 7H-PYRROLOPYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2009-04-22 | — | — | EP | disclosed |
| US-20070135460-A1 | 7H-pyrrolopyrimidine derivatives | CARAVATTI GIORGIO | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135460-A1 | 7H-pyrrolopyrimidine derivatives | DPYD, TYMP, DHPS | RIPK1 3871/4885POLB 85/4885MAP3K11 2012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.